Effect of Lutein and Zeaxanthin on Macular Pigment and Visual Function in Patients with Early Age-related Macular Degeneration
To determine whether supplementation with lutein and zeaxanthin improves macular pigment and visual function in patients with early age-related macular degeneration (AMD). Randomized, double-masked, placebo-controlled trial. Participants with probable AMD who were 50 to 79 years of age were screened...
Saved in:
| Published in | Ophthalmology (Rochester, Minn.) Vol. 119; no. 11; pp. 2290 - 2297 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York, NY
Elsevier Inc
01.11.2012
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | To determine whether supplementation with lutein and zeaxanthin improves macular pigment and visual function in patients with early age-related macular degeneration (AMD).
Randomized, double-masked, placebo-controlled trial.
Participants with probable AMD who were 50 to 79 years of age were screened for study eligibility from the local communities. One hundred eight subjects with early AMD were recruited.
Early AMD patients were assigned randomly to receive 10 mg/day lutein (n = 27), 20 mg/day lutein (n = 27), 10 mg/day lutein plus 10 mg/day zeaxanthin (n = 27); or placebo (n = 27) for 48 weeks. Macular pigment optical density (MPOD) and visual function variables were assessed at baseline, 24 weeks, and 48 weeks.
The primary outcome was MPOD. Secondary outcomes were visual function variables including best-corrected visual acuity (BCVA), contrast sensitivity (CS), photorecovery time, and Amsler grid testing results.
Macular pigment optical density increased significantly by a mean±standard error of 0.076±0.022 density unit in the 20-mg lutein group and 0.058±0.027 density unit in the lutein and zeaxanthin group during 48 weeks. There was a significant dose-response effect for lutein supplementation, and the changes in MPOD from baseline to 48 weeks were correlated negatively with baseline MPOD in all active treatment groups (r = −0.56; P<0.001). At 48 weeks, a trend toward improvement was seen in BCVA, and there was a significant between-group difference in CS at 3 and 6 cycles/degree between the 20-mg lutein group and the placebo group. The increase in MPOD related positively to the reduction in the logarithm of the minimum angle of resolution BCVA (r = −0.31; P<0.01) and the increases in CS at 4 spatial frequencies (r ranging from 0.26 to 0.38; all P<0.05).
Among patients with early AMD, supplementation with lutein and zeaxanthin improved macular pigment, which played a causative role in boosting visual function and might prevent the progression of AMD. Future studies are required to evaluate the effect of these carotenoids on the incidence of late AMD.
The author(s) have no proprietary or commercial interest in any materials discussed in this article. |
|---|---|
| AbstractList | To determine whether supplementation with lutein and zeaxanthin improves macular pigment and visual function in patients with early age-related macular degeneration (AMD).PURPOSETo determine whether supplementation with lutein and zeaxanthin improves macular pigment and visual function in patients with early age-related macular degeneration (AMD).Randomized, double-masked, placebo-controlled trial.DESIGNRandomized, double-masked, placebo-controlled trial.Participants with probable AMD who were 50 to 79 years of age were screened for study eligibility from the local communities. One hundred eight subjects with early AMD were recruited.PARTICIPANTSParticipants with probable AMD who were 50 to 79 years of age were screened for study eligibility from the local communities. One hundred eight subjects with early AMD were recruited.Early AMD patients were assigned randomly to receive 10 mg/day lutein (n = 27), 20 mg/day lutein (n = 27), 10 mg/day lutein plus 10 mg/day zeaxanthin (n = 27); or placebo (n = 27) for 48 weeks. Macular pigment optical density (MPOD) and visual function variables were assessed at baseline, 24 weeks, and 48 weeks.INTERVENTIONEarly AMD patients were assigned randomly to receive 10 mg/day lutein (n = 27), 20 mg/day lutein (n = 27), 10 mg/day lutein plus 10 mg/day zeaxanthin (n = 27); or placebo (n = 27) for 48 weeks. Macular pigment optical density (MPOD) and visual function variables were assessed at baseline, 24 weeks, and 48 weeks.The primary outcome was MPOD. Secondary outcomes were visual function variables including best-corrected visual acuity (BCVA), contrast sensitivity (CS), photorecovery time, and Amsler grid testing results.MAIN OUTCOME MEASURESThe primary outcome was MPOD. Secondary outcomes were visual function variables including best-corrected visual acuity (BCVA), contrast sensitivity (CS), photorecovery time, and Amsler grid testing results.Macular pigment optical density increased significantly by a mean ± standard error of 0.076 ± 0.022 density unit in the 20-mg lutein group and 0.058 ± 0.027 density unit in the lutein and zeaxanthin group during 48 weeks. There was a significant dose-response effect for lutein supplementation, and the changes in MPOD from baseline to 48 weeks were correlated negatively with baseline MPOD in all active treatment groups (r = -0.56; P<0.001). At 48 weeks, a trend toward improvement was seen in BCVA, and there was a significant between-group difference in CS at 3 and 6 cycles/degree between the 20-mg lutein group and the placebo group. The increase in MPOD related positively to the reduction in the logarithm of the minimum angle of resolution BCVA (r = -0.31; P<0.01) and the increases in CS at 4 spatial frequencies (r ranging from 0.26 to 0.38; all P<0.05).RESULTSMacular pigment optical density increased significantly by a mean ± standard error of 0.076 ± 0.022 density unit in the 20-mg lutein group and 0.058 ± 0.027 density unit in the lutein and zeaxanthin group during 48 weeks. There was a significant dose-response effect for lutein supplementation, and the changes in MPOD from baseline to 48 weeks were correlated negatively with baseline MPOD in all active treatment groups (r = -0.56; P<0.001). At 48 weeks, a trend toward improvement was seen in BCVA, and there was a significant between-group difference in CS at 3 and 6 cycles/degree between the 20-mg lutein group and the placebo group. The increase in MPOD related positively to the reduction in the logarithm of the minimum angle of resolution BCVA (r = -0.31; P<0.01) and the increases in CS at 4 spatial frequencies (r ranging from 0.26 to 0.38; all P<0.05).Among patients with early AMD, supplementation with lutein and zeaxanthin improved macular pigment, which played a causative role in boosting visual function and might prevent the progression of AMD. Future studies are required to evaluate the effect of these carotenoids on the incidence of late AMD.CONCLUSIONSAmong patients with early AMD, supplementation with lutein and zeaxanthin improved macular pigment, which played a causative role in boosting visual function and might prevent the progression of AMD. Future studies are required to evaluate the effect of these carotenoids on the incidence of late AMD. To determine whether supplementation with lutein and zeaxanthin improves macular pigment and visual function in patients with early age-related macular degeneration (AMD). Randomized, double-masked, placebo-controlled trial. Participants with probable AMD who were 50 to 79 years of age were screened for study eligibility from the local communities. One hundred eight subjects with early AMD were recruited. Early AMD patients were assigned randomly to receive 10 mg/day lutein (n = 27), 20 mg/day lutein (n = 27), 10 mg/day lutein plus 10 mg/day zeaxanthin (n = 27); or placebo (n = 27) for 48 weeks. Macular pigment optical density (MPOD) and visual function variables were assessed at baseline, 24 weeks, and 48 weeks. The primary outcome was MPOD. Secondary outcomes were visual function variables including best-corrected visual acuity (BCVA), contrast sensitivity (CS), photorecovery time, and Amsler grid testing results. Macular pigment optical density increased significantly by a mean ± standard error of 0.076 ± 0.022 density unit in the 20-mg lutein group and 0.058 ± 0.027 density unit in the lutein and zeaxanthin group during 48 weeks. There was a significant dose-response effect for lutein supplementation, and the changes in MPOD from baseline to 48 weeks were correlated negatively with baseline MPOD in all active treatment groups (r = -0.56; P<0.001). At 48 weeks, a trend toward improvement was seen in BCVA, and there was a significant between-group difference in CS at 3 and 6 cycles/degree between the 20-mg lutein group and the placebo group. The increase in MPOD related positively to the reduction in the logarithm of the minimum angle of resolution BCVA (r = -0.31; P<0.01) and the increases in CS at 4 spatial frequencies (r ranging from 0.26 to 0.38; all P<0.05). Among patients with early AMD, supplementation with lutein and zeaxanthin improved macular pigment, which played a causative role in boosting visual function and might prevent the progression of AMD. Future studies are required to evaluate the effect of these carotenoids on the incidence of late AMD. Purpose To determine whether supplementation with lutein and zeaxanthin improves macular pigment and visual function in patients with early age-related macular degeneration (AMD). Design Randomized, double-masked, placebo-controlled trial. Participants Participants with probable AMD who were 50 to 79 years of age were screened for study eligibility from the local communities. One hundred eight subjects with early AMD were recruited. Intervention Early AMD patients were assigned randomly to receive 10 mg/day lutein (n = 27), 20 mg/day lutein (n = 27), 10 mg/day lutein plus 10 mg/day zeaxanthin (n = 27); or placebo (n = 27) for 48 weeks. Macular pigment optical density (MPOD) and visual function variables were assessed at baseline, 24 weeks, and 48 weeks. Main Outcome Measures The primary outcome was MPOD. Secondary outcomes were visual function variables including best-corrected visual acuity (BCVA), contrast sensitivity (CS), photorecovery time, and Amsler grid testing results. Results Macular pigment optical density increased significantly by a mean±standard error of 0.076±0.022 density unit in the 20-mg lutein group and 0.058±0.027 density unit in the lutein and zeaxanthin group during 48 weeks. There was a significant dose-response effect for lutein supplementation, and the changes in MPOD from baseline to 48 weeks were correlated negatively with baseline MPOD in all active treatment groups ( r = −0.56; P <0.001). At 48 weeks, a trend toward improvement was seen in BCVA, and there was a significant between-group difference in CS at 3 and 6 cycles/degree between the 20-mg lutein group and the placebo group. The increase in MPOD related positively to the reduction in the logarithm of the minimum angle of resolution BCVA ( r = −0.31; P <0.01) and the increases in CS at 4 spatial frequencies ( r ranging from 0.26 to 0.38; all P <0.05). Conclusions Among patients with early AMD, supplementation with lutein and zeaxanthin improved macular pigment, which played a causative role in boosting visual function and might prevent the progression of AMD. Future studies are required to evaluate the effect of these carotenoids on the incidence of late AMD. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article. To determine whether supplementation with lutein and zeaxanthin improves macular pigment and visual function in patients with early age-related macular degeneration (AMD). Randomized, double-masked, placebo-controlled trial. Participants with probable AMD who were 50 to 79 years of age were screened for study eligibility from the local communities. One hundred eight subjects with early AMD were recruited. Early AMD patients were assigned randomly to receive 10 mg/day lutein (n = 27), 20 mg/day lutein (n = 27), 10 mg/day lutein plus 10 mg/day zeaxanthin (n = 27); or placebo (n = 27) for 48 weeks. Macular pigment optical density (MPOD) and visual function variables were assessed at baseline, 24 weeks, and 48 weeks. The primary outcome was MPOD. Secondary outcomes were visual function variables including best-corrected visual acuity (BCVA), contrast sensitivity (CS), photorecovery time, and Amsler grid testing results. Macular pigment optical density increased significantly by a mean±standard error of 0.076±0.022 density unit in the 20-mg lutein group and 0.058±0.027 density unit in the lutein and zeaxanthin group during 48 weeks. There was a significant dose-response effect for lutein supplementation, and the changes in MPOD from baseline to 48 weeks were correlated negatively with baseline MPOD in all active treatment groups (r = −0.56; P<0.001). At 48 weeks, a trend toward improvement was seen in BCVA, and there was a significant between-group difference in CS at 3 and 6 cycles/degree between the 20-mg lutein group and the placebo group. The increase in MPOD related positively to the reduction in the logarithm of the minimum angle of resolution BCVA (r = −0.31; P<0.01) and the increases in CS at 4 spatial frequencies (r ranging from 0.26 to 0.38; all P<0.05). Among patients with early AMD, supplementation with lutein and zeaxanthin improved macular pigment, which played a causative role in boosting visual function and might prevent the progression of AMD. Future studies are required to evaluate the effect of these carotenoids on the incidence of late AMD. The author(s) have no proprietary or commercial interest in any materials discussed in this article. |
| Author | Huang, Yang-Mu Xiao, Xin Qian, Fang Lin, Xiao-Ming Ma, Le Sun, Ting-Ting Dong, Peng-Cheng Pang, Hong-Lei Zou, Zhi-Yong Yan, Shao-Fang Wang, Xun Dou, Hong-Liang Lu, Xin-Rong Xu, Xian-Rong |
| Author_xml | – sequence: 1 givenname: Le surname: Ma fullname: Ma, Le organization: Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China – sequence: 2 givenname: Shao-Fang surname: Yan fullname: Yan, Shao-Fang organization: Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China – sequence: 3 givenname: Yang-Mu surname: Huang fullname: Huang, Yang-Mu organization: Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China – sequence: 4 givenname: Xin-Rong surname: Lu fullname: Lu, Xin-Rong organization: Peking University Eye Center, Peking University Third Hospital, Beijing, China – sequence: 5 givenname: Fang surname: Qian fullname: Qian, Fang organization: Peking University Eye Center, Peking University Third Hospital, Beijing, China – sequence: 6 givenname: Hong-Lei surname: Pang fullname: Pang, Hong-Lei organization: Peking University Eye Center, Peking University Third Hospital, Beijing, China – sequence: 7 givenname: Xian-Rong surname: Xu fullname: Xu, Xian-Rong organization: Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China – sequence: 8 givenname: Zhi-Yong surname: Zou fullname: Zou, Zhi-Yong organization: Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China – sequence: 9 givenname: Peng-Cheng surname: Dong fullname: Dong, Peng-Cheng organization: Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China – sequence: 10 givenname: Xin surname: Xiao fullname: Xiao, Xin organization: Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China – sequence: 11 givenname: Xun surname: Wang fullname: Wang, Xun organization: Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China – sequence: 12 givenname: Ting-Ting surname: Sun fullname: Sun, Ting-Ting organization: Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China – sequence: 13 givenname: Hong-Liang surname: Dou fullname: Dou, Hong-Liang email: douhongliang3736@sina.cn organization: Peking University Eye Center, Peking University Third Hospital, Beijing, China – sequence: 14 givenname: Xiao-Ming surname: Lin fullname: Lin, Xiao-Ming email: linbjmu@bjmu.edu.cn organization: Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26777255$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22858124$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVkl-L1DAUxYOsuLOr30CkL4IvrUmbpq2IsKyzKoy44J8HX8JtejuTMZOOSao7L_vZTXfGFQRZfAohv3PCPeeekCM7WCTkMaMZo0w8X2fDdhVWkOWU5RkVGWX8Hpmxkjcpr1hxRGYRY6ngOT0mJ96vKaVCFPwBOc7zuqxZzmfket73qEIy9MliDKhtArZLviJcgQ2reB1s8h7UaMAll3q5QRtuiC_aj2CSi9GqoCMTyUsIOj775KcOq2QOzuySsyWmDg0E7G5tXuMSLTqYdA_J_R6Mx0eH85R8vph_On-bLj68eXd-tkhVSWlIRd0Wbata2sXxOBZtzSkW0BUCoBJCtXVZVZx2WNdxMlHWtGwKaFpBGWuYqItT8mzvu3XD9xF9kBvtFRoDFofRS8aKRsQgGxHRJwd0bDfYya3TG3A7-TuzCDw9AOAVmN6BVdr_4URVVXlZRo7vOeUG7x32twijcqpQruW-QjlVKKmQscIoe_GXTOlwE1ZwoM1d4ld7McYwf2h00qtYisJOu1iz7Ab9vwbKaKvjnN9wh349jM7GoiSTPmrkx2nFpg1jOaUlL4to8PLfBnf__wtjyOGQ |
| CODEN | OPHTDG |
| CitedBy_id | crossref_primary_10_1016_j_ophtha_2013_09_038 crossref_primary_10_1093_nutrit_nuv005 crossref_primary_10_1016_j_preteyeres_2014_07_001 crossref_primary_10_1186_s40942_016_0044_9 crossref_primary_10_1371_journal_pone_0089069 crossref_primary_10_1007_s10384_018_0588_3 crossref_primary_10_1039_D3FO02105J crossref_primary_10_3390_molecules21081052 crossref_primary_10_1097_MD_0000000000001641 crossref_primary_10_3390_antiox13050568 crossref_primary_10_7759_cureus_79481 crossref_primary_10_1038_s41598_020_66962_2 crossref_primary_10_1097_IAE_0000000000001450 crossref_primary_10_3109_19390211_2014_988577 crossref_primary_10_1167_tvst_10_2_18 crossref_primary_10_1186_s12937_017_0301_2 crossref_primary_10_3390_horticulturae8090820 crossref_primary_10_3390_nu5051823 crossref_primary_10_7717_peerj_cs_1940 crossref_primary_10_1159_000441705 crossref_primary_10_1016_j_onano_2022_100098 crossref_primary_10_1016_j_preteyeres_2021_101037 crossref_primary_10_3390_nu10091321 crossref_primary_10_1016_j_msec_2016_08_029 crossref_primary_10_1155_2015_523027 crossref_primary_10_1016_j_exer_2017_12_015 crossref_primary_10_1097_IAE_0000000000000893 crossref_primary_10_1177_1120672120920537 crossref_primary_10_1155_2015_564738 crossref_primary_10_3390_encyclopedia1040093 crossref_primary_10_1371_journal_pone_0135211 crossref_primary_10_1001_jama_2022_6381 crossref_primary_10_3390_antiox10121857 crossref_primary_10_1371_journal_pone_0139257 crossref_primary_10_1016_j_addr_2021_113886 crossref_primary_10_3390_nu13082553 crossref_primary_10_1016_j_nutres_2013_10_011 crossref_primary_10_1016_j_nutres_2016_02_007 crossref_primary_10_1017_S0007114516003895 crossref_primary_10_3390_nu14204273 crossref_primary_10_1016_j_advnut_2024_100216 crossref_primary_10_1146_annurev_nutr_071715_051110 crossref_primary_10_3390_nu14040827 crossref_primary_10_1159_000363327 crossref_primary_10_3390_antiox8100469 crossref_primary_10_3390_pharmaceutics12090798 crossref_primary_10_1016_j_tifs_2015_12_005 crossref_primary_10_1016_j_nut_2013_05_012 crossref_primary_10_1016_j_tifs_2021_10_017 crossref_primary_10_1080_08820538_2021_2022165 crossref_primary_10_3390_nu9020120 crossref_primary_10_1016_j_nut_2013_03_001 crossref_primary_10_1007_s00417_013_2376_6 crossref_primary_10_1556_1326_2017_00313 crossref_primary_10_1016_j_fct_2021_112328 crossref_primary_10_1017_S0007114517002483 crossref_primary_10_1186_s13068_018_1270_1 crossref_primary_10_1080_10837450_2023_2270032 crossref_primary_10_1038_ejcn_2017_152 crossref_primary_10_3390_nu16234124 crossref_primary_10_1016_j_cnd_2018_02_002 crossref_primary_10_3390_nu16193273 crossref_primary_10_3390_nu16101415 crossref_primary_10_3390_nu12051321 crossref_primary_10_3233_JAD_150199 crossref_primary_10_17925_EOR_2018_12_1_39 crossref_primary_10_3390_molecules22040610 crossref_primary_10_3390_antiox13091114 crossref_primary_10_1016_j_abb_2015_02_004 crossref_primary_10_1016_j_tjnut_2024_02_028 crossref_primary_10_3389_fnut_2024_1422468 crossref_primary_10_3390_horticulturae7090272 crossref_primary_10_1016_j_clnesp_2023_05_009 crossref_primary_10_1016_j_jnutbio_2021_108615 crossref_primary_10_1155_2022_6321778 crossref_primary_10_3390_jpm14060653 crossref_primary_10_1155_2013_549174 crossref_primary_10_1016_j_foodchem_2020_127195 crossref_primary_10_1155_2016_9035745 crossref_primary_10_1016_j_bbalip_2020_158664 crossref_primary_10_1097_IAE_0000000000000174 crossref_primary_10_3390_nu16091276 crossref_primary_10_1016_j_plantsci_2022_111575 crossref_primary_10_3390_nu14194005 crossref_primary_10_1093_nutrit_nuad037 crossref_primary_10_1017_jns_2014_10 crossref_primary_10_1007_s00210_024_03376_1 crossref_primary_10_1371_journal_pone_0298132 crossref_primary_10_3390_antiox10081255 crossref_primary_10_3390_nu8070426 crossref_primary_10_1136_bjophthalmol_2014_305503 crossref_primary_10_3390_nu12113271 crossref_primary_10_1002_jsfa_11109 crossref_primary_10_1007_s12013_017_0795_4 crossref_primary_10_1038_s41598_019_44632_2 crossref_primary_10_1111_aos_13408 crossref_primary_10_3390_antiox9111044 crossref_primary_10_1167_iovs_62_9_18 crossref_primary_10_14479_jkoos_2020_25_2_175 crossref_primary_10_1002_14651858_CD000254_pub5 crossref_primary_10_1002_14651858_CD000254_pub4 crossref_primary_10_1016_j_maturitas_2013_05_006 crossref_primary_10_3390_nu5072405 crossref_primary_10_1167_iovs_17_23699 crossref_primary_10_33808_clinexphealthsci_810526 crossref_primary_10_3310_hta22270 crossref_primary_10_3390_antiox10111743 crossref_primary_10_1136_bjophthalmol_2016_308418 crossref_primary_10_1155_2015_865179 crossref_primary_10_1371_journal_pone_0227048 crossref_primary_10_3390_nu13072441 crossref_primary_10_1016_j_preteyeres_2021_101015 crossref_primary_10_1017_S0954422424000015 crossref_primary_10_3945_an_116_013177 |
| Cites_doi | 10.1167/iovs.10-5898 10.1001/archopht.123.11.1484 10.1016/S1350-9462(02)00003-4 10.1093/ajcn/87.6.1837 10.1016/S1529-1839(04)70049-4 10.1001/archopht.122.4.564 10.1111/j.1753-4887.2005.tb00122.x 10.1016/j.ophtha.2007.06.015 10.1167/iovs.02-1243 10.1167/iovs.10-5460 10.1056/NEJMoa042760 10.1007/s00417-006-0289-3 10.1007/s00417-010-1461-3 10.1016/j.exer.2006.12.010 10.1093/ajcn/87.5.1464 10.1016/j.ophtha.2007.03.083 10.1006/exer.2002.2050 10.1016/j.visres.2004.11.017 10.1016/S0140-6736(08)61759-6 10.1021/bi101906y 10.1167/iovs.10-5664 10.1167/iovs.08-2493 10.1016/j.ajo.2003.11.069 10.1159/000315531 10.1016/j.abb.2004.05.016 10.1056/NEJMra0801537 10.1016/j.exer.2005.10.004 10.1001/jama.294.24.3101 10.1002/jsfa.905 10.1167/iovs.06-0914 10.1080/02713680802647654 10.1017/S0007114511004260 10.1097/OPX.0b013e3181a72980 |
| ContentType | Journal Article |
| Copyright | 2012 American Academy of Ophthalmology American Academy of Ophthalmology 2014 INIST-CNRS Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2012 American Academy of Ophthalmology – notice: American Academy of Ophthalmology – notice: 2014 INIST-CNRS – notice: Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ophtha.2012.06.014 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1549-4713 |
| EndPage | 2297 |
| ExternalDocumentID | 22858124 26777255 10_1016_j_ophtha_2012_06_014 S0161642012005453 1_s2_0_S0161642012005453 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: NSFC-30872113 |
| GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 123 1B1 1CY 1P~ 1~5 29N 4.4 457 4G. 53G 5RE 5VS 7-5 71M AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAXUO ABCQX ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACIUM ACNCT ACRPL ACVFH ADCNI ADMUD ADNMO AEFWE AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AGCQF AGQPQ AIGII AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY C5W CS3 DU5 EBS EFJIC EFKBS EJD F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ IHE J1W K-O KOM L7B M27 M41 MO0 N4W N9A NQ- O9- OF- OPF OQ~ P2P R2- ROL RPZ SDG SEL SES SSZ UHS UNMZH UV1 WH7 X7M XH2 XPP Z5R ZGI ZXP ADPAM RIG AAIAV AGZHU AHPSJ ALXNB ZA5 AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c500t-68b3bbcb0d1544e3b840e3ad36aa766cb857740de882856580593a9b601191683 |
| ISSN | 0161-6420 1549-4713 |
| IngestDate | Fri Jul 11 07:24:22 EDT 2025 Mon Jul 21 05:55:52 EDT 2025 Wed Apr 02 07:27:13 EDT 2025 Tue Jul 01 03:37:24 EDT 2025 Thu Apr 24 22:58:07 EDT 2025 Fri Feb 23 02:22:14 EST 2024 Sun Feb 23 10:19:57 EST 2025 Tue Aug 26 19:03:10 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | Human Macula Zeaxanthin Eye disease Retinopathy Xanthophyll Pigments Early Age related macular degeneration Ophthalmology Carotenoid |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c500t-68b3bbcb0d1544e3b840e3ad36aa766cb857740de882856580593a9b601191683 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 22858124 |
| PQID | 1139620196 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1139620196 pubmed_primary_22858124 pascalfrancis_primary_26777255 crossref_primary_10_1016_j_ophtha_2012_06_014 crossref_citationtrail_10_1016_j_ophtha_2012_06_014 elsevier_sciencedirect_doi_10_1016_j_ophtha_2012_06_014 elsevier_clinicalkeyesjournals_1_s2_0_S0161642012005453 elsevier_clinicalkey_doi_10_1016_j_ophtha_2012_06_014 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-11-01 |
| PublicationDateYYYYMMDD | 2012-11-01 |
| PublicationDate_xml | – month: 11 year: 2012 text: 2012-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | New York, NY |
| PublicationPlace_xml | – name: New York, NY – name: United States |
| PublicationTitle | Ophthalmology (Rochester, Minn.) |
| PublicationTitleAlternate | Ophthalmology |
| PublicationYear | 2012 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Barker, Snodderly, Johnson (bib8) 2011; 52 Olmedilla, Granado, Blanco (bib15) 2001; 81 Newsome, Negreiro (bib22) 2009; 34 Thomson, Toyoda, Delori (bib34) 2002; 75 Sasamoto, Gomi, Sawa (bib36) 2011; 52 LaRowe, Mares, Snodderly (bib27) 2008; 115 Kuo, Kuo, Tiong (bib20) 2011; 249 (bib17) 2005; 123 Nolan, Kenny, O'Regan (bib24) 2010; 44 Kant, Graubard (bib28) 2008; 87 Gragoudas, Adamis, Cunningham (bib4) 2004; 351 Richer (bib14) 1999; 70 Jager, Mieler, Miller (bib1) 2008; 358 Cho, Hankinson, Rosner (bib10) 2008; 87 Brown, Lindsey (bib30) 2009; 86 Hiraoka, Okamoto, Ishii (bib21) 2007; 48 van Leeuwen, Boekhoorn, Vingerling (bib11) 2005; 294 Kim, Nakanishi, Itagaki, Sparrow (bib6) 2006; 82 Sasaki, Ozawa, Kurihara (bib7) 2009; 50 Kruger, Rucker, Hu (bib35) 2005; 45 Stringham, Hammond (bib33) 2005; 63 Ma, Dou, Wu (bib12) 2012; 107 Richer, Stiles, Statkute (bib13) 2004; 75 Wooten, Hammond (bib32) 2002; 21 Klein, Peto, Bird, Vannewkirk (bib2) 2004; 137 Rapp, Maple, Choi (bib25) 2000; 41 Tan, Wang, Flood (bib9) 2008; 115 Chiang, Xie, Keeffe (bib31) 2011; 52 Coleman, Chan, Ferris, Chew (bib16) 2008; 372 Trieschmann, Heimes, Hense, Pauleikhoff (bib18) 2006; 244 Li, Vachali, Frederick, Bernstein (bib29) 2011; 50 (bib3) 2004; 122 Neuringer, Sandstrom, Johnson, Snodderly (bib5) 2004; 45 Bone, Landrum, Mayne (bib23) 2001; 42 Trieschmann, Beatty, Nolan (bib26) 2007; 84 Delori (bib19) 2004; 430 Brown (10.1016/j.ophtha.2012.06.014_bib30) 2009; 86 Klein (10.1016/j.ophtha.2012.06.014_bib2) 2004; 137 Wooten (10.1016/j.ophtha.2012.06.014_bib32) 2002; 21 Gragoudas (10.1016/j.ophtha.2012.06.014_bib4) 2004; 351 Bone (10.1016/j.ophtha.2012.06.014_bib23) 2001; 42 Stringham (10.1016/j.ophtha.2012.06.014_bib33) 2005; 63 Li (10.1016/j.ophtha.2012.06.014_bib29) 2011; 50 Olmedilla (10.1016/j.ophtha.2012.06.014_bib15) 2001; 81 Kim (10.1016/j.ophtha.2012.06.014_bib6) 2006; 82 LaRowe (10.1016/j.ophtha.2012.06.014_bib27) 2008; 115 Kuo (10.1016/j.ophtha.2012.06.014_bib20) 2011; 249 Trieschmann (10.1016/j.ophtha.2012.06.014_bib26) 2007; 84 Chiang (10.1016/j.ophtha.2012.06.014_bib31) 2011; 52 Kruger (10.1016/j.ophtha.2012.06.014_bib35) 2005; 45 Newsome (10.1016/j.ophtha.2012.06.014_bib22) 2009; 34 Tan (10.1016/j.ophtha.2012.06.014_bib9) 2008; 115 Hiraoka (10.1016/j.ophtha.2012.06.014_bib21) 2007; 48 Delori (10.1016/j.ophtha.2012.06.014_bib19) 2004; 430 Barker (10.1016/j.ophtha.2012.06.014_bib8) 2011; 52 Thomson (10.1016/j.ophtha.2012.06.014_bib34) 2002; 75 Cho (10.1016/j.ophtha.2012.06.014_bib10) 2008; 87 Sasaki (10.1016/j.ophtha.2012.06.014_bib7) 2009; 50 (10.1016/j.ophtha.2012.06.014_bib3) 2004; 122 (10.1016/j.ophtha.2012.06.014_bib17) 2005; 123 Nolan (10.1016/j.ophtha.2012.06.014_bib24) 2010; 44 Neuringer (10.1016/j.ophtha.2012.06.014_bib5) 2004; 45 Richer (10.1016/j.ophtha.2012.06.014_bib13) 2004; 75 Ma (10.1016/j.ophtha.2012.06.014_bib12) 2012; 107 Richer (10.1016/j.ophtha.2012.06.014_bib14) 1999; 70 van Leeuwen (10.1016/j.ophtha.2012.06.014_bib11) 2005; 294 Jager (10.1016/j.ophtha.2012.06.014_bib1) 2008; 358 Trieschmann (10.1016/j.ophtha.2012.06.014_bib18) 2006; 244 Coleman (10.1016/j.ophtha.2012.06.014_bib16) 2008; 372 Kant (10.1016/j.ophtha.2012.06.014_bib28) 2008; 87 Sasamoto (10.1016/j.ophtha.2012.06.014_bib36) 2011; 52 Rapp (10.1016/j.ophtha.2012.06.014_bib25) 2000; 41 |
| References_xml | – volume: 75 start-page: 529 year: 2002 end-page: 542 ident: bib34 article-title: Long term dietary supplementation with zeaxanthin reduces photoreceptor death in light-damaged Japanese quail publication-title: Exp Eye Res – volume: 372 start-page: 1835 year: 2008 end-page: 1845 ident: bib16 article-title: Age-related macular degeneration publication-title: Lancet – volume: 84 start-page: 718 year: 2007 end-page: 728 ident: bib26 article-title: Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study publication-title: Exp Eye Res – volume: 52 start-page: 2790 year: 2011 end-page: 2795 ident: bib31 article-title: Identifying the critical success factors in the coverage of low vision services using the classification analysis and regression tree methodology publication-title: Invest Ophthalmol Vis Sci – volume: 294 start-page: 3101 year: 2005 end-page: 3107 ident: bib11 article-title: Dietary intake of antioxidants and risk of age-related macular degeneration publication-title: JAMA – volume: 45 start-page: 3234 year: 2004 end-page: 3243 ident: bib5 article-title: Nutritional manipulation of primate retinas: I publication-title: Invest Ophthalmol Vis Sci – volume: 82 start-page: 828 year: 2006 end-page: 839 ident: bib6 article-title: Photooxidation of A2-PE, a photoreceptor outer segment fluorophore, and protection by lutein and zeaxanthin publication-title: Exp Eye Res – volume: 87 start-page: 1837 year: 2008 end-page: 1843 ident: bib10 article-title: Prospective study of lutein/zeaxanthin intake and risk of age-related macular degeneration publication-title: Am J Clin Nutr – volume: 249 start-page: 601 year: 2011 end-page: 605 ident: bib20 article-title: Visual acuity as measured with Landolt C chart and Early Treatment of Diabetic Retinopathy Study (ETDRS) chart publication-title: Graefes Arch Clin Exp Ophthalmol – volume: 87 start-page: 1464 year: 2008 end-page: 1471 ident: bib28 article-title: Ethnic and socioeconomic differences in variability in nutritional biomarkers publication-title: Am J Clin Nutr – volume: 50 start-page: 1433 year: 2009 end-page: 1439 ident: bib7 article-title: Neuroprotective effect of an antioxidant, lutein, during retinal inflammation publication-title: Invest Ophthalmol Vis Sci – volume: 75 start-page: 216 year: 2004 end-page: 230 ident: bib13 article-title: Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial) publication-title: Optometry – volume: 50 start-page: 2541 year: 2011 end-page: 2549 ident: bib29 article-title: Identification of StARD3 as a lutein-binding protein in the macula of the primate retina publication-title: Biochemistry – volume: 52 start-page: 3934 year: 2011 end-page: 3942 ident: bib8 article-title: Nutritional manipulation of primate retinas: V publication-title: Invest Ophthalmol Vis Sci – volume: 21 start-page: 225 year: 2002 end-page: 240 ident: bib32 article-title: Macular pigment: influences on visual acuity and visibility publication-title: Prog Retin Eye Res – volume: 52 start-page: 927 year: 2011 end-page: 932 ident: bib36 article-title: Effect of cataract in evaluation of macular pigment optical density by autofluorescence spectrometry publication-title: Invest Ophthalmol Vis Sci – volume: 351 start-page: 2805 year: 2004 end-page: 2816 ident: bib4 article-title: Pegaptanib for neovascular age-related macular degeneration publication-title: N Engl J Med – volume: 45 start-page: 1265 year: 2005 end-page: 1274 ident: bib35 article-title: Accommodation with and without short-wavelength-sensitive cones and chromatic aberration publication-title: Vision Res – volume: 115 start-page: 334 year: 2008 end-page: 341 ident: bib9 article-title: Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study publication-title: Ophthalmology – volume: 244 start-page: 1565 year: 2006 end-page: 1574 ident: bib18 article-title: Macular pigment optical density measurement in autofluorescence imaging: comparison of one- and two-wavelength methods publication-title: Graefes Arch Clin Exp Ophthalmol – volume: 44 start-page: 131 year: 2010 end-page: 139 ident: bib24 article-title: Macular pigment optical density in an ageing Irish population: the Irish Longitudinal Study on Ageing publication-title: Ophthalmic Res – volume: 41 start-page: 1200 year: 2000 end-page: 1209 ident: bib25 article-title: Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina publication-title: Invest Ophthalmol Vis Sci – volume: 358 start-page: 2606 year: 2008 end-page: 2617 ident: bib1 article-title: Age-related macular degeneration publication-title: N Engl J Med – volume: 137 start-page: 486 year: 2004 end-page: 495 ident: bib2 article-title: The epidemiology of age-related macular degeneration publication-title: Am J Ophthalmol – volume: 122 start-page: 564 year: 2004 end-page: 572 ident: bib3 article-title: Prevalence of age-related macular degeneration in the United States publication-title: Arch Ophthalmol – volume: 81 start-page: 904 year: 2001 end-page: 909 ident: bib15 article-title: Lutein in patients with cataracts and age-related macular degeneration: a long-term supplementation study publication-title: J Sci Food Agric – volume: 42 start-page: 235 year: 2001 end-page: 240 ident: bib23 article-title: Macular pigment in donor eyes with and without AMD: a case-controlled study publication-title: Invest Ophthalmol Vis Sci – volume: 34 start-page: 162 year: 2009 end-page: 170 ident: bib22 article-title: Reproducible measurement of macular light flash recovery time using a novel device can indicate the presence and worsening of macular diseases publication-title: Curr Eye Res – volume: 70 start-page: 24 year: 1999 end-page: 36 ident: bib14 article-title: ARMD—pilot (case series) environmental intervention data publication-title: J Am Optom Assoc – volume: 123 start-page: 1484 year: 2005 end-page: 1498 ident: bib17 article-title: The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report no. 17 publication-title: Arch Ophthalmol – volume: 430 start-page: 156 year: 2004 end-page: 162 ident: bib19 article-title: Autofluorescence method to measure macular pigment optical densities fluorometry and autofluorescence imaging publication-title: Arch Biochem Biophys – volume: 63 start-page: 59 year: 2005 end-page: 64 ident: bib33 article-title: Dietary lutein and zeaxanthin: possible effects on visual function publication-title: Nutr Rev – volume: 48 start-page: 550 year: 2007 end-page: 556 ident: bib21 article-title: Contrast sensitivity function and ocular higher-order aberrations following overnight orthokeratology publication-title: Invest Ophthalmol Vis Sci – volume: 107 start-page: 350 year: 2012 end-page: 359 ident: bib12 article-title: Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis publication-title: Br J Nutr – volume: 115 start-page: 876 year: 2008 end-page: 883 ident: bib27 article-title: Macular pigment density and age-related maculopathy in the Carotenoids in Age-Related Eye Disease Study: an ancillary study of the Women's Health Initiative publication-title: Ophthalmology – volume: 86 start-page: 572 year: 2009 end-page: 576 ident: bib30 article-title: Contrast insensitivity: the critical immaturity in infant visual performance publication-title: Optom Vis Sci – volume: 52 start-page: 3934 year: 2011 ident: 10.1016/j.ophtha.2012.06.014_bib8 article-title: Nutritional manipulation of primate retinas: V publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-5898 – volume: 123 start-page: 1484 year: 2005 ident: 10.1016/j.ophtha.2012.06.014_bib17 article-title: The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report no. 17 publication-title: Arch Ophthalmol doi: 10.1001/archopht.123.11.1484 – volume: 21 start-page: 225 year: 2002 ident: 10.1016/j.ophtha.2012.06.014_bib32 article-title: Macular pigment: influences on visual acuity and visibility publication-title: Prog Retin Eye Res doi: 10.1016/S1350-9462(02)00003-4 – volume: 87 start-page: 1837 year: 2008 ident: 10.1016/j.ophtha.2012.06.014_bib10 article-title: Prospective study of lutein/zeaxanthin intake and risk of age-related macular degeneration publication-title: Am J Clin Nutr doi: 10.1093/ajcn/87.6.1837 – volume: 75 start-page: 216 year: 2004 ident: 10.1016/j.ophtha.2012.06.014_bib13 article-title: Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial) publication-title: Optometry doi: 10.1016/S1529-1839(04)70049-4 – volume: 122 start-page: 564 year: 2004 ident: 10.1016/j.ophtha.2012.06.014_bib3 article-title: Prevalence of age-related macular degeneration in the United States publication-title: Arch Ophthalmol doi: 10.1001/archopht.122.4.564 – volume: 63 start-page: 59 year: 2005 ident: 10.1016/j.ophtha.2012.06.014_bib33 article-title: Dietary lutein and zeaxanthin: possible effects on visual function publication-title: Nutr Rev doi: 10.1111/j.1753-4887.2005.tb00122.x – volume: 115 start-page: 876 year: 2008 ident: 10.1016/j.ophtha.2012.06.014_bib27 article-title: Macular pigment density and age-related maculopathy in the Carotenoids in Age-Related Eye Disease Study: an ancillary study of the Women's Health Initiative publication-title: Ophthalmology doi: 10.1016/j.ophtha.2007.06.015 – volume: 45 start-page: 3234 year: 2004 ident: 10.1016/j.ophtha.2012.06.014_bib5 article-title: Nutritional manipulation of primate retinas: I publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.02-1243 – volume: 52 start-page: 2790 year: 2011 ident: 10.1016/j.ophtha.2012.06.014_bib31 article-title: Identifying the critical success factors in the coverage of low vision services using the classification analysis and regression tree methodology publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-5460 – volume: 351 start-page: 2805 year: 2004 ident: 10.1016/j.ophtha.2012.06.014_bib4 article-title: Pegaptanib for neovascular age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJMoa042760 – volume: 244 start-page: 1565 year: 2006 ident: 10.1016/j.ophtha.2012.06.014_bib18 article-title: Macular pigment optical density measurement in autofluorescence imaging: comparison of one- and two-wavelength methods publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-006-0289-3 – volume: 249 start-page: 601 year: 2011 ident: 10.1016/j.ophtha.2012.06.014_bib20 article-title: Visual acuity as measured with Landolt C chart and Early Treatment of Diabetic Retinopathy Study (ETDRS) chart publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-010-1461-3 – volume: 84 start-page: 718 year: 2007 ident: 10.1016/j.ophtha.2012.06.014_bib26 article-title: Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study publication-title: Exp Eye Res doi: 10.1016/j.exer.2006.12.010 – volume: 87 start-page: 1464 year: 2008 ident: 10.1016/j.ophtha.2012.06.014_bib28 article-title: Ethnic and socioeconomic differences in variability in nutritional biomarkers publication-title: Am J Clin Nutr doi: 10.1093/ajcn/87.5.1464 – volume: 115 start-page: 334 year: 2008 ident: 10.1016/j.ophtha.2012.06.014_bib9 article-title: Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2007.03.083 – volume: 41 start-page: 1200 year: 2000 ident: 10.1016/j.ophtha.2012.06.014_bib25 article-title: Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina publication-title: Invest Ophthalmol Vis Sci – volume: 75 start-page: 529 year: 2002 ident: 10.1016/j.ophtha.2012.06.014_bib34 article-title: Long term dietary supplementation with zeaxanthin reduces photoreceptor death in light-damaged Japanese quail publication-title: Exp Eye Res doi: 10.1006/exer.2002.2050 – volume: 45 start-page: 1265 year: 2005 ident: 10.1016/j.ophtha.2012.06.014_bib35 article-title: Accommodation with and without short-wavelength-sensitive cones and chromatic aberration publication-title: Vision Res doi: 10.1016/j.visres.2004.11.017 – volume: 372 start-page: 1835 year: 2008 ident: 10.1016/j.ophtha.2012.06.014_bib16 article-title: Age-related macular degeneration publication-title: Lancet doi: 10.1016/S0140-6736(08)61759-6 – volume: 50 start-page: 2541 year: 2011 ident: 10.1016/j.ophtha.2012.06.014_bib29 article-title: Identification of StARD3 as a lutein-binding protein in the macula of the primate retina publication-title: Biochemistry doi: 10.1021/bi101906y – volume: 70 start-page: 24 year: 1999 ident: 10.1016/j.ophtha.2012.06.014_bib14 article-title: ARMD—pilot (case series) environmental intervention data publication-title: J Am Optom Assoc – volume: 52 start-page: 927 year: 2011 ident: 10.1016/j.ophtha.2012.06.014_bib36 article-title: Effect of cataract in evaluation of macular pigment optical density by autofluorescence spectrometry publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-5664 – volume: 50 start-page: 1433 year: 2009 ident: 10.1016/j.ophtha.2012.06.014_bib7 article-title: Neuroprotective effect of an antioxidant, lutein, during retinal inflammation publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.08-2493 – volume: 137 start-page: 486 year: 2004 ident: 10.1016/j.ophtha.2012.06.014_bib2 article-title: The epidemiology of age-related macular degeneration publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2003.11.069 – volume: 44 start-page: 131 year: 2010 ident: 10.1016/j.ophtha.2012.06.014_bib24 article-title: Macular pigment optical density in an ageing Irish population: the Irish Longitudinal Study on Ageing publication-title: Ophthalmic Res doi: 10.1159/000315531 – volume: 430 start-page: 156 year: 2004 ident: 10.1016/j.ophtha.2012.06.014_bib19 article-title: Autofluorescence method to measure macular pigment optical densities fluorometry and autofluorescence imaging publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2004.05.016 – volume: 358 start-page: 2606 year: 2008 ident: 10.1016/j.ophtha.2012.06.014_bib1 article-title: Age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJMra0801537 – volume: 42 start-page: 235 year: 2001 ident: 10.1016/j.ophtha.2012.06.014_bib23 article-title: Macular pigment in donor eyes with and without AMD: a case-controlled study publication-title: Invest Ophthalmol Vis Sci – volume: 82 start-page: 828 year: 2006 ident: 10.1016/j.ophtha.2012.06.014_bib6 article-title: Photooxidation of A2-PE, a photoreceptor outer segment fluorophore, and protection by lutein and zeaxanthin publication-title: Exp Eye Res doi: 10.1016/j.exer.2005.10.004 – volume: 294 start-page: 3101 year: 2005 ident: 10.1016/j.ophtha.2012.06.014_bib11 article-title: Dietary intake of antioxidants and risk of age-related macular degeneration publication-title: JAMA doi: 10.1001/jama.294.24.3101 – volume: 81 start-page: 904 year: 2001 ident: 10.1016/j.ophtha.2012.06.014_bib15 article-title: Lutein in patients with cataracts and age-related macular degeneration: a long-term supplementation study publication-title: J Sci Food Agric doi: 10.1002/jsfa.905 – volume: 48 start-page: 550 year: 2007 ident: 10.1016/j.ophtha.2012.06.014_bib21 article-title: Contrast sensitivity function and ocular higher-order aberrations following overnight orthokeratology publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.06-0914 – volume: 34 start-page: 162 year: 2009 ident: 10.1016/j.ophtha.2012.06.014_bib22 article-title: Reproducible measurement of macular light flash recovery time using a novel device can indicate the presence and worsening of macular diseases publication-title: Curr Eye Res doi: 10.1080/02713680802647654 – volume: 107 start-page: 350 year: 2012 ident: 10.1016/j.ophtha.2012.06.014_bib12 article-title: Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis publication-title: Br J Nutr doi: 10.1017/S0007114511004260 – volume: 86 start-page: 572 year: 2009 ident: 10.1016/j.ophtha.2012.06.014_bib30 article-title: Contrast insensitivity: the critical immaturity in infant visual performance publication-title: Optom Vis Sci doi: 10.1097/OPX.0b013e3181a72980 |
| SSID | ssj0006634 |
| Score | 2.4577863 |
| Snippet | To determine whether supplementation with lutein and zeaxanthin improves macular pigment and visual function in patients with early age-related macular... Purpose To determine whether supplementation with lutein and zeaxanthin improves macular pigment and visual function in patients with early age-related macular... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2290 |
| SubjectTerms | Aged Biological and medical sciences Contrast Sensitivity Dietary Supplements Dose-Response Relationship, Drug Double-Blind Method Drug Therapy, Combination Feeding Behavior Female Humans Lutein - administration & dosage Lutein - metabolism Macular Degeneration - drug therapy Macular Degeneration - metabolism Male Medical sciences Middle Aged Miscellaneous Ophthalmology Photic Stimulation Prospective Studies Retina - physiology Retina - radiation effects Retinal Pigments - metabolism Retinopathies Rhodopsin - metabolism Surveys and Questionnaires Visual Acuity - physiology Xanthophylls - administration & dosage Xanthophylls - metabolism Zeaxanthins |
| Title | Effect of Lutein and Zeaxanthin on Macular Pigment and Visual Function in Patients with Early Age-related Macular Degeneration |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0161642012005453 https://www.clinicalkey.es/playcontent/1-s2.0-S0161642012005453 https://dx.doi.org/10.1016/j.ophtha.2012.06.014 https://www.ncbi.nlm.nih.gov/pubmed/22858124 https://www.proquest.com/docview/1139620196 |
| Volume | 119 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLaqTUJICHFfuUxG4tVVbnaTxwqoJrbCNG1QeInsxL1MI6loIyEe-EP8SY7tkzSFjm28RI1lu7HPF59LzoWQV5GvNEjKMRMyi1mUTzSTYeizXCV9LnUc5zYT0-i9ODiL3o35uNP51fJaqlaql_3YGlfyP1SFNqCriZK9AWWbSaEBfgN94QoUhuu1aIyph42ZvzJVK-2XgC9afoftmsEtUHYknaPp8XzauJN_nC9N0MgQWFrt6njs0qtirJvLejyYamZDXXTeTPNGT22e6oacKNd-WMxWM3nx1WV0smYJrMTlfPOLoteyOYysxHrUYOozWmFnsmRDibzUYg2t2dBhykZV3X5UmcbxvGAnJfZGw4UfYARfy5YpfAbqj7dxGOMBiqjz22dr4AqLIp-G2_5WHuDMEee90q7ceO8FNkWrC1bdTLn9BytsHBRr37fz1M2SmllS4wJoiqbvBqCTBDtkd3B48umwYfwgvGEqebeuOlLTuhP-_TSXSUJ3FnIJ7-fEFVa5XPOxEtDpPXIXVRc6cDi8Tzq6eEBujdA54yH56eBIywl1cKQANrqGIy0LijiiCEfbw8GR1nCk0LOGIzVwpBaOtAXHZpo2HB-Rs-Hb09cHDMt7sIx73oqJWIVKZcrLTUYoHao48nQo81BI2RciUzEH3cTL4cAIYtA7YlN9UiZKmDSFvojDx2SnKAu9R2gCclgC3GeipY645CqacE_nQWLK3SUJ75Kw3uo0w9z3pgTLRfovQncJa0YtXO6XK_rzmoppHdcMnDgFYF4xrr9tnF7iUbNM_XQJnY0npvANsnxjC4542B6JErOThK_xn_sbMGsWGIg-gJvDlr2scZcCxzGfEWWhywoeBpRGEZi8Wl3yxAFyPRooZVSGpzfcumfk9vqIeE52Vt8q_QKk_ZXax7fsNxX__s0 |
| linkProvider | Library Specific Holdings |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+Lutein+and+Zeaxanthin+on+Macular+Pigment+and+Visual+Function+in+Patients+with+Early+Age-related+Macular+Degeneration&rft.jtitle=Ophthalmology+%28Rochester%2C+Minn.%29&rft.au=Ma%2C+Le&rft.au=Yan%2C+Shao-Fang&rft.au=Huang%2C+Yang-Mu&rft.au=Lu%2C+Xin-Rong&rft.date=2012-11-01&rft.issn=0161-6420&rft.volume=119&rft.issue=11&rft.spage=2290&rft.epage=2297&rft_id=info:doi/10.1016%2Fj.ophtha.2012.06.014&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_ophtha_2012_06_014 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01616420%2FS0161642011X00210%2Fcov150h.gif |